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Chronic obstructive pulmonary disease (COPD) is a common, highly debili-
tating disease of the airways, primarily caused by smoking. Chronic inflam-
mation and structural remodelling are key pathological features of this
disease, in part caused by the aberrant function of airway smooth muscle
(ASM) cells under the regulation of transforming growth factor (TGF)-b.
miRNA are short, noncoding gene transcripts involved in the negative regula-
tion of specific target genes, through their interactions with mRNA. Previous
studies have proposed that mRNA-145 (miR-145) may interact with SMAD3,
an important downstream signalling molecule of the TGF-b pathway. TGF-b
was used to stimulate primary human ASM cells isolated from healthy non-
smokers, healthy smokers and COPD patients. This resulted in a TGF-b-
dependent increase in CXCL8 and IL-6 release, most notably in the cells
from COPD patients. TGF-b stimulation increased SMAD3 expression, only
in cells from COPD patients, with a concurrent increased miR-145 expres-
sion. Regulation of miR-145 was found to be negatively controlled by path-
ways involving the MAP kinases, MEK-1/2 and p38 MAPK. Subsequent,
overexpression of miR-145 (using synthetic mimics) in ASM cells from
patients with COPD suppressed IL-6 and CXCL8 release, to levels compara-
ble to the nonsmoker controls. Therefore, this study suggests that miR-145
negatively regulates pro-inflammatory cytokine release from ASM cells in
COPD by targeting SMAD3.
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Chronic obstructive pulmonary disease (COPD) is a
chronic inflammatory condition of the lung of high
global prevalence [1] and is associated with high mor-
bidity, mortality and socioeconomic cost [2]; moreover,
its contribution to deaths worldwide is predicted to
increase over the course of both the current and next
decade [3].
Chronic obstructive pulmonary disease is a heteroge-
neous condition, primarily affecting the lung, but often
with significant systemic features, which can augment
the morbidity of the disorder and hamper its manage-
ment [2]. The pulmonary component of the disease
refers to a progressive and largely irreversible obstruc-
tion of airflow, due to a pathological combination of
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narrowing of the small airways, parenchymal destruc-
tion and structural remodelling [4]. The aberrant
remodelling occurs in addition, or in response, to the
ongoing and worsening inflammation [5]. It is associ-
ated with architectural alterations to the bronchi [6],
small airways and parenchymal tissue and affects the
epithelium, its underlying extracellular matrix and the
surrounding smooth muscle and these changes have
been correlated with disease severity [7]. Although the
primary cause of COPD in more economically devel-
oped countries is cigarette smoking, the majority of
heavy smokers do not develop the disease [8] and indi-
cators for determining those that will be affected
remain elusive.
An increased ASM mass has been observed in both
the large and small airways in COPD [6], which cor-
relates with disease severity [7]. Whether increased
ASM mass in COPD is due to either hypertrophy or
hyperproliferation, or a combination of both has not
been definitively determined. ASM cells have also
been shown to produce a number of cytokines,
chemokines and growth factors in response to a vari-
ety of inflammatory stimuli, which may contribute
towards the inflammatory process in COPD [9].
Among these secreted cytokines are CXC chemokine
ligand 8 (CXCL8) and interleukin 6 (IL-6) both of
which have been found to be elevated in the sputum
of patients with COPD; even more so during exacer-
bations [10].
Transforming growth factor (TGF)-b is a pleiotropic
cytokine that stimulates ASM proliferation and pro-
inflammatory cytokine production [11,12], and elevated
TGF-b secretion by pulmonary epithelial cells from
patients with COPD has been observed in comparison
to healthy controls [13]. TGF-b signalling is typically
through the Smad-dependent pathway [14] although
other signalling pathways can also be involved, includ-
ing the nuclear factor-jB (NF-jB) pathway, pathways
involving mitogen-activated protein kinases (MAPKs)
and the Wingless/integrase-1 (WNT) pathway [15].
In addition to the transcription of mRNA, which
forms the first step of the ‘central dogma of molecular
biology’, noncoding RNA are transcribed from DNA
[16]. miRNA bind, in a complementary manner, to the
30 end of their target mRNA and instigate there sup-
pression/degradation [16]. Cell proliferation has been
shown to be regulated by microRNA-221 (miR-221) in
ASM cells from patients with asthma [12]; in a human
epithelial cell line [17]; and in murine vascular smooth
muscle cells (VSMCs) [18]. IL-6 and CXCL8 secretion
has also been shown to be attenuated by miRNA; by
miR-221 in ASM cells from patients with asthma [12];
and by miR-146a and miR-146b in human alveolar
epithelial cells [19,20]. Our previous studies have
helped to identify miR-145 as a potential key regulator
of airway smooth muscle function in COPD. Firstly, it
is highly expressed in the healthy lung [21] and in
healthy ASM cells specifically [22]. It has also been
shown to be overexpressed in the airways of patients
with cystic fibrosis, and to correlate with a decrease in
SMAD3 expression [23]. A number of human and ani-
mal models have linked miR-145 to mechanisms that
could also contribute towards the development of
COPD [24,25]. Smooth muscle cell proliferation corre-
lated inversely with expression levels of miR-145 in
murine [26–28], leporine [29] and human [28] vascula-
tures. Moreover, exposure to cigarette smoke has been
shown to affect expression levels of miR-145 in the
lungs of rats [30].
We hypothesized that increased IL-6 and CXCL8
release from the ASM cells of COPD patients is medi-
ated by the TGF-b–induced expression of miR-145.
We examined the effects of TGF-b upon ASM IL-6
and CXCL8 release from patients with COPD, and in
healthy nonsmokers and healthy smokers. We then
examined the regulation of miR-145 with specific
kinase inhibitors. Finally, we examined the effects of
modulating the expression levels of miR-145 in these
cells on cytokine release and on the phosphorylation
of SMAD3. miR-145 controls the excessive cytokine
release observed in ASM cells from patients with
COPD, by reducing SMAD3 phosphorylation.
Materials and methods
Primary human ASM cell culture
Primary human ASM cells were previously dissected from
the lungs of healthy nonsmokers, healthy smokers and
patients with COPD; disease and smoking status were
defined according to guidelines produced by the American
Thoracic Society [31]. Healthy smokers had a smoking his-
tory of at least 10 pack years. There were significant differ-
ences between FEV1 in litres, FEV1 percent predicted, and
FEV1/FVC ratio between smokers and patients with COPD
compared with nonsmokers but matched for age and smok-
ing history (Table 1).
ASM cells were cultured and plated as previously
described [11,12,22,32]. ASM cells were plated onto 96-well
plates for the measurement of cytokine release, and six well
plates for RNA and protein extraction. Confluent cells
were growth-arrested by FCS deprivation for 24 h in Dul-
becco’s Modified Eagle’s Medium supplemented with
sodium pyruvate (1 mM), L-glutamine (2 mM), nonessential
amino acids (1 : 100), penicillin (100 UmL1)/streptomycin
(100 mgmL1), amphotericin B (1.5 mgmL1) and BSA
(0.1%). Passages 3–4 from nine different donors were used.
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Cells were stimulated in triplicate  TGF-b at the indi-
cated concentrations.
Alternatively, ASM cells were cultured for 1 h in the
presence or absence of the indicated concentrations of
TPCA-1 (an IKK-2 inhibitor), PD098059 (a MEK-1/2 inhi-
bitor), SP600125 (a JNK-1/2 inhibitor) and SB 203580 (a
p38 MAP kinase inhibitor) and then stimulated with
1 ngmL1 of TGF-b for 24 h. All inhibitors were obtained
from Calbiochem. The supernatants were removed, and IL-
6 and CXCL8 levels were determined by DuoSet ELISA
(R&D Systems, Abingdon, UK).
miRNA and mRNA Expression
The human (hsa)-miR-145 and SMAD3 expression levels
were measured as previously described [11,12,22].
Transfection with miR-145 mimics and controls
ASM cells were transfected as previously described [11,12].
A mimic for miR-145 and controls were obtained from
Ambion/Applied Biosystems, Ltd. (Paisley, UK). Trans-
fected cells were plated into 96-well or 6-well plates, and
left to adhere overnight before being serum starved for 6 h
before stimulation with 1 ngmL1 TGF-b for the indicated
times.
Western blotting
Proteins were measured as previously described [12,32,33].
Antibodies against human phospho-S423-S425-Smad3 and
total Smad3 were purchased from AbCam (Cambridge,
UK).
Data analysis
Data were analysed using GRAPHPAD PRISM, version 5.03
(GraphPad Software, San Diego, CA). Data were not
normally distributed (as assessed by the Kolmogorov–Smir-
nov test), and therefore groups were compared using the
Dunn nonparametric test. All data are expressed as
means  SEMs. Significance was defined as a P value of
less than 0.05.
Results
The effect of TGF-b stimulation on CXCL8 and
IL-6 release and SMAD3 and miR-145 expression
by ASM cells after 24 h
ASM cells were stimulated with 2.5% FCS and TGF-
b at the indicated concentrations (0.001–10 ngmL1)
for 24 h. TGF-b induced a concentration-dependent
increase in CXCL8 and IL-6 release from ASM cells
which plateaued at 1 ngmL1 in the nonsmokers
(P < 0.05), smokers (P < 0.01) and COPD (P < 0.001)
cells (Fig. 1A,B). A significant increase in CXCL8
release was observed in the COPD ASM cells com-
pared to the nonsmokers (P < 0.01) when the ASM
cells were stimulated with 1 ngmL1 of TGF-b
(Fig. 1A). Furthermore, there was significant increase
in IL-6 release between the nonsmokers and smokers
(P < 0.01), nonsmokers and COPDs (P < 0.001), and
the smoker and COPD ASM cells (P < 0.05)
(Fig. 1B).
TGF-b (0.01 ngmL1) induced an increase in
SMAD3 expression in ASM cells from COPD
patients ~ 60-fold higher than baseline (P < 0.001;
Fig. 1C). Relatively little change to SMAD3 expres-
sion was seen in the nonsmokers and smokers com-
pared to unstimulated cells. miR-145 expression in
ASM cells from COPD patients exhibited a concen-
tration dependent increase which plateaued at
1 ngmL1 (P < 0.01) (Fig. 1D). A significant increase
in expression was observed in the COPD ASM cells
compared to the nonsmokers and smokers (both
P < 0.01) (Fig. 1D).
The effects of specific kinase inhibitors on CXCL8
and IL-6 release by ASM cells stimulated with
FCS and TGF-b after 24 h
In previous studies, we and others have demonstrated
that cytokines can induce activation of IKK2/NF-jB
and the MAP kinases, ERK-1/2, JNK-1/2 and p38
MAP kinase in ASM cells and that these are inhibited
in the presence of the selective pharmacological inhibi-
tors of these [34–43]. We therefore used the biological
active concentrations of these inhibitors to examine
the role of the NF-jB and MAP kinases pathways
during miR-145 expression.
Table 1. Patient characteristics.
Nonsmokers Smokers COPD
n 9 9 9
Age (years) 66.4  12.72 59.2  7.6 65.4  6.6
Sex (♂ – ♀) 7 – 2 4 – 5 5 – 5
Pack years
smoking
N/A 29.25  3.3 38.32  26.92
FEV1 (L) 4.02  0.48 3.12  0.78 1.76  0.45
FEV1
(% Predicted)
104.23  7.28 101.5  4.51 77  21.97
FEV1/FVC (%) 78.89  5.98 77.57  3.32 38.88  15.75
PC20 (mgmL1) > 16 > 16 Too severe
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity;
PC20, provocative concentration of methacholine causing a 20% fall
in FEV1. Data shown as mean  SEM.
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Following 1 h pre-treatment with inhibitors, ASM
cells were stimulated with TGF-b (1 ngmL1) and
the generation of IL-6 (Fig. 2A,D,G,J), CXCL8
(Fig. 2B,E,H,K) and miR-145 (Fig. 2C,F,I,L) were
determined at 24 h. Exposure to TPCA-1 completely
inhibited production of IL-6 and CXCL8 in the non-
smokers at 10 lM, and a significant reduction was
observed in the COPD ASM cells (both P < 0.05)
(Fig. 2A,B). No effect was observed upon miR-145
expression (Fig. 2C). The MEK-1/2 inhibitor (10 lM)
also attenuated IL-6 and CXCL8 production (both
P < 0.05) (Fig. 2D,E). Interestingly, a significant
increase in miR-145 expression was observed in the
COPD ASM cells (P < 0.05) (Fig. 2F). Inhibition of
the JNK-1/2 kinase demonstrated no effect upon
either cytokine release or miR-145 expression
(Fig. 2G,H,I). In contrast, inhibition of the p38
MAP kinase had differential actions upon cytokine
and miR-145 production. Blocking p38 MAP kinase
inhibited CXCL8 but not IL-6 in both the non-
smoker and COPD ASM cells (Fig. 2J,K), and a sig-
nificant increase in miR-145 expression was observed
in the COPD ASM cells (Fig. 2L). Overall, pharma-
cological studies indicate that TGF-b- induced miR-
145 expression is regulated via an MEK-1/2- and
p38-dependent pathway.
The effect upon TGF-b-stimulated ASM cells of
miR-145 overexpression on CXCL8 and IL-6
release
To clarify the role of miR-145, we examined the effect
of overexpressing miR-145 on TGF-b–induced CXCL8
and IL-6 release. Transfection using Amaxa electropo-
ration (Lonza, Slough, UK) showed that miR-145
mimics (100 nM) inhibited CXCL8 release by approxi-
mately 47% (P < 0.01) and IL-6 release by approxi-
mately 49% (P < 0.001), to levels comparably seen in
the healthy smokers (Fig. 3A,B). Altering the endoge-
nous levels of miR-145 exerted no effect in either
healthy or smoker ASM cells or those from patients
with severe asthma. To confirm efficient transfection,
we undertook parallel studies that examined the effects
of a small, interfering RNA (100 nM) targeted to IL-6.
As demonstrated previously [12,41], we showed a
reduction in IL-6 release induced by TGF-b stimula-
tion in ASM cells (data not shown), with no effect
upon cell viability (data not shown).
Fig. 1. Effect of increasing concentrations
of transforming growth factor–b (TGF-b)
on airway smooth muscle (ASM) CXCL8
(A) and IL-6 release (B), SMAD3 (C) and
miR-145 (D) expression from the ASM
cells of non-smokers, smokers and
patients with COPD at 24 h. Points
represent the means  SEMs from nine
ASM donors in each group. */$/#P < 0.05;
**/$$/##P < 0.01; ***/###/$$$P < 0.001.
Asterisks indicate comparison with no
TGF-b control. Hash signs indicate COPD
vs. nonsmoker ASM cells. Dollar signs
indicate COPD vs. smoker ASM cells. Plus
signs indicate smoker vs. nonsmoker ASM
cells.
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Fig. 2. Effect of inhibitors of IKK2 and MAP kinases upon TGF-b-induced IL-6 and CXCL8 release, and miR-145 expression from the ASM
cells of nonsmokers and patients with COPD at 24 h. ASM cells were pretreated for 60 min with the indicated concentrations of the
inhibitors of IKK-2 (TPCA-1), MEK-1/2 (PD098059), JNK-1/2 (SP600125) and p38 MAP kinase (SB203580). Following exposure to vehicle
control or TGF-b (1 ngmL1) for 24 h, the release of IL-6 and CXCL8 was determined by ELISA. miR-145 expression was measured by RT-
PCR. Points represent the means  SEM of nine ASM donors in each group. */#P < 0.05; ##P < 0.01; ###P < 0.001. Asterisks indicate
stimulated nonsmoker comparison with no TGF-b control. Hash signs indicate stimulated COPD comparison with no TGF-b control.
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Effects of miR-145 on SMAD3
We next determined whether miR-145 could regulate
SMAD3 phosphorylation. As previously demonstrated
[33], TGF-b (1 ngmL1) increased SMAD3 phospho-
rylation in the nonsmoker ASM cells at 24 h
(P < 0.05) (Fig. 3C). For the first time, we demon-
strate that there is a slight increase in phosphorylation
in the non-smokers, and an even greater degree of
phosphorylation in the ASM cells from COPD
patients induced by TGF-b (P < 0.001) (Fig. 3C). The
miR-145 mimic (100 nM) decreased the TGF-b-induced
phosphorylation of SMAD3 in the COPD ASM cells
by approximately 50% (P < 0.05) (Fig. 3C), and
demonstrated no effect upon either the nonsmoker or
smoker ASM cells.
Discussion
We have made several important observations regard-
ing the behaviour of ASM cells from patients with
COPD. First, we showed that TGF-b increased both
ASM IL-6 and CXCL8 release in the COPD patients
to a greater degree than those from the nonsmoker
subjects. We also observed a concurrent increase in the
expression of both SMAD3 and miR-145 in the ASM
cells from the COPD patients. We next investigated
the mechanisms that regulate the expression of miR-
145. We showed that expression of miR-145 is medi-
ated, at least in part, through activation of MEK-1/2
and p38 in ASM cells from COPD patients. Examina-
tion of the effect of these MAP kinase inhibitors upon
generation of inflammatory mediators showed that
Fig. 3. Effects of the overexpression of miR-145 in the ASM cells of nonsmokers, smokers and patients with COPD at 24 h. ASM cells
were electroporated in the presence of buffer, control mimic or miR-145 mimic. Cells were then exposed to vehicle control or 1 ngmL1
TGF-b and the release of CXCL8 (A) and IL-6 (B) was measured by ELISA at 24 h. Furthermore, p-SMAD3 was measure by western blotting
(C). Points represent the means  SEMs from nine ASM donors in each group. */#P < 0.05; **/##/++P < 0.01; ***/###P < 0.001.
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IL-6 release was mediated via IKK2 and MEK-1/2
while CXCL8 release was mediated via IKK2, MEK-
1/2 and p38 in both the ASM cohorts, from nonsmok-
ers and those with COPD. Finally, we found that
miR-145 regulates the enhanced IL-6 and CXCL8
release seen in the ASM cells from patients with
COPD, that could be partly through the control of
SMAD3 (Summarized in Fig. 4).
Previous observations have described the effect of
inducing hyperproliferation of ASM cells with TGF-b
in both asthma [11,12] and COPD [44]. This is the first
time that TGF-b has been shown to induce both IL-6
and CXCL8 release from primary ASM cells isolated
from individuals with COPD. The regulation of smooth
muscle cell phenotype has previously been shown to be
correlated with expression of miR-145. Specifically,
miR-145 has been demonstrated to regulate smooth
muscle cell fate [26,45], the contractile phenotype of
VSMCs [27,46], and acts a novel VSMC phenotypic
marker in murine models [28], and prevent vein graft
disease in rabbits [29]. Interestingly, exposure to cigar-
ette smoke has been shown to affect expression levels of
miR-145 in the lungs of rats [30], and has been found to
be differentially expressed in lung homogenates in rats
with COPD [47]. Furthermore, miR-145 (along with
others) has recently been proposed to be a promising
plasma based biomarker for the diagnosis of COPD
[48]. This is the first time that a role for miR-145 in the
ASM cells from COPD patients has been reported. We
have shown that expression of miR-145 is through acti-
vation of both MEK-1/2 and p38. Interestingly, Hu
et al. [49], have reported that activation of MEK-1/2
suppresses miR-145 expression in VSMCs, and Kent
et al. [50], demonstrate that miR-145 expression is
inhibited through activation of the MAPK and JNK
pathways in colorectal cancer. Furthermore, in car-
diomyocytes, the protective activity of miR-145 is asso-
ciated with modulation of both MEK-1/2 and JNK [51]
and in gastric mucosal epithelial cell regulation of miR-
145 involves JNK [52]. Similar to our results, p38 has
previously been shown to be linked to miR-145 induc-
tion in VSMCs [53] and Hong et al. [54], suggest that
the p38 MAPK signalling pathway promotes miRNA
biogenesis by facilitating the nuclear localization of
p68. Clearly, the regulation of miR-145 is, unsurpris-
ingly, cell type specific.
Finally, we examined the effect of increasing miR-
145 expression in ASM cells from COPD patients
upon IL-6 and CXCL8 release. Although studies
have suggested a correlation between miR-145 expres-
sion and IL-6 & CXCL8 release [55–58], we show
for the first time that increasing the expression of
Fig. 4. SMAD3 dependent regulation of IL-6 & CXCL8 release by TGF-b-induced miR-145 expression. In response to TGF-b stimulation,
MEK-1/2 and p38 activation results in increased miR-145 expression. The concurrent increase in expression and phosphorylation of SMAD3,
is regulated by miR-145 to prevent further generation and release of IL-6 & CXCL8.
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miR-145 can reduce the levels of IL-6 & CXCL8
release from the COPD ASM cells to levels compara-
ble to that of the nonsmoker ASM cells. miR-145 is
proposed to target SMAD3 in systemic sclerosis
(SSc) [59], cystic fibrosis [23], cartilage dysfunction
[60], nasopharyngeal cancer [61] and in hypertrophic
scar fibroblasts (HSFBs) [62], we show here that this
may also be the case in ASM cells from patients
with COPD.
Interestingly, miR-145 is also likely to be important
in regulating ASM cells in asthma, as it is highly
expressed in the healthy lung [21] and in healthy ASM
cells specifically [22], and inhibition of miR-145 inhibits
eosinophilic inflammation, mucus hypersecretion, TH2
cytokine production and airway hyperresponsiveness
in house dust mite-induced allergic mouse airways [63].
In conclusion, miR-145 is vital in controlling the
increased inflammatory response of human ASM cells
in patients with COPD. This finding may open a new
avenue in COPD therapeutics by targeting of miRNA-
145 and diagnosis by its detection.
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